Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival.

Epithelial-to-mesenchymal transition (EMT) is a key process associated with tumor progression and metastasis. To define molecular features associated with EMT states, we undertook an integrative approach combining mRNA, miRNA, DNA methylation, and proteomic profiles of 38 cell populations representative of the genomic heterogeneity in lung adenocarcinoma. The resulting data were integrated with functional profiles consisting of cell invasiveness, adhesion, and motility. A subset of cell lines that were readily defined as epithelial or mesenchymal based on their morphology and E-cadherin and vimentin expression elicited distinctive molecular signatures. Other cell populations displayed intermediate/hybrid states of EMT, with mixed epithelial and mesenchymal characteristics. A dominant proteomic feature of aggressive hybrid cell lines was upregulation of cytoskeletal and actin-binding proteins, a signature shared with mesenchymal cell lines. Cytoskeletal reorganization preceded loss of E-cadherin in epithelial cells in which EMT was induced by TGFβ. A set of transcripts corresponding to the mesenchymal protein signature enriched in cytoskeletal proteins was found to be predictive of survival in independent datasets of lung adenocarcinomas. Our findings point to an association between cytoskeletal and actin-binding proteins, a mesenchymal or hybrid EMT phenotype and invasive properties of lung adenocarcinomas.

[1]  V. Keshamouni,et al.  Epithelial-mesenchymal transition in tumor metastasis: a method to the madness. , 2009, Future oncology.

[2]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Eshel Ben-Jacob,et al.  MicroRNA-based regulation of epithelial–hybrid–mesenchymal fate determination , 2013, Proceedings of the National Academy of Sciences.

[4]  Caicun Zhou,et al.  Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial–mesenchymal transition in non‐small cell lung cancer , 2009, Respirology.

[5]  G. Hampton,et al.  DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[6]  A. Feinberg,et al.  Genome-scale epigenetic reprogramming during epithelial to mesenchymal transition , 2011, Nature Structural &Molecular Biology.

[7]  A. Dimmler,et al.  The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. , 2008, Cancer research.

[8]  D G Wilkinson,et al.  Control of cell behavior during vertebrate development by Slug, a zinc finger gene. , 1994, Science.

[9]  Jing Yang,et al.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. , 2012, Cancer cell.

[10]  T. Lecuit,et al.  Breaking down EMT , 2008, Nature Cell Biology.

[11]  J. Thiery Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[12]  HighWire Press,et al.  Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 1983 .

[13]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[14]  Elizabeth Garrett-Mayer,et al.  ZEB1-responsive genes in non-small cell lung cancer. , 2011, Cancer letters.

[15]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[16]  E. Hay,et al.  Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. , 2005, Cells, tissues, organs.

[17]  Robert A. Weinberg,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[18]  I. Gelman,et al.  Pivotal Role of AKAP12 in the Regulation of Cellular Adhesion Dynamics: Control of Cytoskeletal Architecture, Cell Migration, and Mitogenic Signaling , 2012, Journal of signal transduction.

[19]  S. Dedhar,et al.  The Role of Epithelial– Mesenchymal Transition in Cancer Metastasis , 2015 .

[20]  J. Thiery,et al.  Epithelium‐mesenchyme interconversion as example of epithelial plasticity , 1993, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[21]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[22]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[23]  D. Nanba,et al.  Changes in adhesive properties of epithelial cells during early morphogenesis of the mammary gland , 2001, Development, growth & differentiation.

[24]  Diane D. Liu,et al.  Epithelial-to-Mesenchymal Transition in the Development and Progression of Adenocarcinoma and Squamous Cell Carcinoma of the Lung , 2009, Modern Pathology.

[25]  Keitaro Matsuo,et al.  Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Rubino,et al.  The role of epithelial-mesenchymal transition in cancer pathology. , 2007, Pathology.

[27]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[28]  I. Fidler,et al.  Biological heterogeneity of cancer , 2012, Human vaccines & immunotherapeutics.

[29]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[30]  J. Rossant,et al.  FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak. , 2001, Developmental cell.

[31]  E. Hay,et al.  Transforming Growth Factor-β Signaling during Epithelial-Mesenchymal Transformation: Implications for Embryogenesis and Tumor Metastasis , 2005, Cells Tissues Organs.

[32]  J. Clements,et al.  Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression , 2007, Journal of cellular physiology.

[33]  R. Nusse,et al.  Convergence of Wnt, ß-Catenin, and Cadherin Pathways , 2004, Science.

[34]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[35]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[36]  Christopher A. Maher,et al.  A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition , 2011, The Journal of cell biology.

[37]  H. Trompeter,et al.  Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells , 2010, BMC Research Notes.

[38]  Jayanta Debnath,et al.  Modelling glandular epithelial cancers in three-dimensional cultures , 2005, Nature Reviews Cancer.

[39]  M. Herlyn,et al.  Comparative Secretome Analysis of Epithelial and Mesenchymal Subpopulations of Head and Neck Squamous Cell Carcinoma Identifies S100A4 as a Potential Therapeutic Target* , 2013, Molecular & Cellular Proteomics.

[40]  David Dunson,et al.  Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[41]  Lan Xu,et al.  miR-21 and miR-31 Converge on TIAM1 to Regulate Migration and Invasion of Colon Carcinoma Cells* , 2010, The Journal of Biological Chemistry.

[42]  E. Yi,et al.  Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung. , 2012, Histology and histopathology.

[43]  Richard Simon,et al.  Gene expression-based prognostic signatures in lung cancer: ready for clinical use? , 2010, Journal of the National Cancer Institute.

[44]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Esteller,et al.  Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis , 2011, Oncogene.

[46]  A. Johansson,et al.  A CD44high/EGFRlow Subpopulation within Head and Neck Cancer Cell Lines Shows an Epithelial-Mesenchymal Transition Phenotype and Resistance to Treatment , 2012, PloS one.

[47]  R. Nusse,et al.  Convergence of Wnt, beta-catenin, and cadherin pathways. , 2004, Science.

[48]  M. Mann,et al.  A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC) , 2006, Nature Protocols.

[49]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[50]  Yong Soo Choi,et al.  Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[51]  M. Thiry,et al.  Evidence for a partial epithelial–mesenchymal transition in postnatal stages of rat auditory organ morphogenesis , 2012, Histochemistry and Cell Biology.

[52]  R. Foisner,et al.  The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity , 2007, Oncogene.

[53]  Sabine Tejpar,et al.  Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer , 2013, The Journal of pathology.

[54]  Kwon-Sik Park,et al.  Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. , 2011, Cancer cell.